RU2007102274A - Пиперазиндионы как антагонисты рецептора окситоцина - Google Patents
Пиперазиндионы как антагонисты рецептора окситоцина Download PDFInfo
- Publication number
- RU2007102274A RU2007102274A RU2007102274/04A RU2007102274A RU2007102274A RU 2007102274 A RU2007102274 A RU 2007102274A RU 2007102274/04 A RU2007102274/04 A RU 2007102274/04A RU 2007102274 A RU2007102274 A RU 2007102274A RU 2007102274 A RU2007102274 A RU 2007102274A
- Authority
- RU
- Russia
- Prior art keywords
- dimethyl
- methylpropyl
- inden
- pyridinyl
- dihydro
- Prior art date
Links
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title claims 3
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- -1 2-indanyl Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- UWHCWRQFNKUYCG-QUZACWSFSA-N Epelsiban Chemical compound O=C([C@H](N1[C@@H](C(N[C@@H](C1=O)C1CC2=CC=CC=C2C1)=O)[C@@H](C)CC)C=1C(=NC(C)=CC=1)C)N1CCOCC1 UWHCWRQFNKUYCG-QUZACWSFSA-N 0.000 claims 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- FJIUVOVNAOXCCJ-FIICIXNYSA-N (2r)-2-[(2r,5r)-2-[(2s)-butan-2-yl]-5-(2,3-dihydro-1h-inden-2-yl)-3,6-dioxopiperazin-1-yl]-2-(2,6-dimethylpyridin-3-yl)-n-methylacetamide Chemical compound C1([C@H](C(=O)NC)N2[C@@H](C(N[C@@H](C2=O)C2CC3=CC=CC=C3C2)=O)[C@@H](C)CC)=CC=C(C)N=C1C FJIUVOVNAOXCCJ-FIICIXNYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims 2
- 101800000989 Oxytocin Proteins 0.000 claims 2
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims 2
- 208000005107 Premature Birth Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229960001723 oxytocin Drugs 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- VSVGMFQLOUTETG-FIICIXNYSA-N (2r)-2-[(2r,5r)-2-[(2s)-butan-2-yl]-5-(2,3-dihydro-1h-inden-2-yl)-3,6-dioxopiperazin-1-yl]-2-(4,6-dimethylpyridin-3-yl)-n-methylacetamide Chemical compound C1([C@H](C(=O)NC)N2[C@@H](C(N[C@@H](C2=O)C2CC3=CC=CC=C3C2)=O)[C@@H](C)CC)=CN=C(C)C=C1C VSVGMFQLOUTETG-FIICIXNYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000004279 Oxytocin receptors Human genes 0.000 claims 1
- 108090000876 Oxytocin receptors Proteins 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (15)
1. Соединение общей формулы (I)
в котором R1 означает 2-инданил, R2 означает 1-метилпропил, R3 является группой, выбранной из 2,6-диметил-3-пиридила или 4,6-диметил-3-пиридила, R4 обозначает метил и R5 обозначает водород или метил или R4 и R5 совместно с атомом азота, к которому они присоединены, представляют морфолиногруппу, и его фармацевтически приемлемых производных.
2. Соединение по п.1, выбранное из солей и сольватов соединений формулы (I)
в котором R1 означает 2-инданил, R2 означает 1-метилпропил, R3 является группой, выбранной из 2,6-диметил-3-пиридила или 4,6-диметил-3-пиридила, R4 обозначает метил и R5 обозначает водород или метил или R4 и R5 совместно с атомом азота, к которому они присоединены, представляют морфолиногруппу.
3. Соединение по п.1, в котором R2 обозначает (1S)-1-метилпропил.
4. Соединение по п.1 или 3, выбранное из
(2R)-2-{(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-6-[(1S)-1-метилпропил]-2,5-диоксо-1-пиперазинил}-2-(2,6-диметил-3-пиридинил)-N-метилэтанамида;
(2R)-2-{(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-6-[(1S)-1-метилпропил]-2,5-диоксо-1-пиперазинил}-2-(2,6-диметил-3-пиридинил)-N,N-диметилэтанамида;
(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-1-[(1R)-1-(2,6-диметил-3-пиридинил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1S)-1-метилпропил]-2,5-пиперазиндиона;
(2R)-2-{(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-6-[(1S)-1-метилпропил]-2,5-диоксо-1-пиперазинил}-2-(4,6-диметил-3-пиридинил)-N,N-диметилэтанамида;
(2R)-2-{(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-6-[(1S)-1-метилпропил]-2,5-диоксо-1-пиперазинил}-2-(4,6-диметил-3-пиридинил)-N-метилэтанамида;
(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-1-[(1R)-1-(4,6-диметил-3-пиридинил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1S)-1-метилпропил]-2,5-пиперазиндиона,
и их фармацевтически приемлемых производных.
5. Соединение по любому из пп.1, 2 и 3, выбранное из
(2R)-2-{(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-6-[(1S)-1-метилпропил]-2,5-диоксо-1-пиперазинил}-2-(2,6-диметил-3-пиридинил)-N-метилэтанамида;
(2R)-2-{(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-6-[(1S)-1-метилпропил]-2,5-диоксо-1-пиперазинил}-2-(2,6-диметил-3-пиридинил)-N,N-диметилэтанамида;
(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-1-[(1R)-1-(2,6-диметил-3-пиридинил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1S)-1-метилпропил]-2,5-пиперазиндиона;
(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-1-[(1R)-1-(4,6-диметил-3-пиридинил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1S)-1-метилпропил]-2,5-пиперазиндиона,
и их фармацевтически приемлемых производных.
6. Соединение по любому из пп.1, 2 и 3, выбранное из
(2R)-2-{(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-6-[(1S)-1-метилпропил]-2,5-диоксо-1-пиперазинил}-2-(2,6-диметил-3-пиридинил)-N-метилэтанамида;
(2R)-2-{(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-6-[(1S)-1-метилпропил]-2,5-диоксо-1-пиперазинил}-2-(2,6-диметил-3-пиридинил)-N,N-диметилэтанамида;
(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-1-[(1R)-1-(2,6-диметил-3-пиридинил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1S)-1-метилпропил]-2,5-пиперазиндиона,
и их фармацевтически приемлемых производных.
7. Соединение по любому из п.1, 2 и 3, выбранное из
(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-1-[(1R)-1-(2,6-диметил-3-пиридинил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1S)-1-метилпропил]-2,5-пиперазиндиона;
(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-1-[(1R)-1-(4,6-диметил-3-пиридинил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1S)-1-метилпропил]-2,5-пиперазиндиона,
и их фармацевтически приемлемых производных.
8. Соединение по любому из пп.1, 2 и 3, выбранное из
(3R,6R)-3-(2,3-дигидро-1H-инден-2-ил)-1-[(1R)-1-(2,6-диметил-3-пиридинил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1S)-1-метилпропил]-2,5-пиперазиндиона, и его фармацевтически приемлемых производных.
9. Фармацевтическая композиция, включающая, по крайней мере, одно химическое соединение по любому из пп.1 и 3-8 вместе с одним или несколькими фармацевтически приемлемыми носителями.
10. Соединение по любому из пп.1-3 для использования в терапии.
11. Применение, по крайней мере, одного химического соединения по пп.1 и 3-8 для производства лекарственного средства для противодействия действиям окситоцина на рецептор окситоцина.
12. Применение, по крайней мере, одного химического соединения по пп.1 и 3-8 для производства лекарственного средства для лечения одного или более заболеваний или состояний, выбранных из группы заболеваний: преждевременные роды, дисменорея, эндометриоз и доброкачественная гиперплазия простаты.
13. Способ лечения или предотвращения заболеваний или состояний, опосредованных действием окситоцина, который включает введение млекопитающим, если в этом есть необходимость, эффективного количества, по крайней мере, одного химического соединения по любому из пп.1 и 3-8.
14. Способ по п.13, в котором заболевание или состояние выбирается из преждевременных родов, дисменореи, эндометриоза и доброкачественной гиперплазии простаты.
15. Способ получения соединений формулы (I) по п.1, который включает
взаимодействие соединения формулы (III)
в котором R1, R2 и R3 имеют значения, определенные в п.1 и R6 обозначает 2-гидроксифенил, с 1,1'-карбонилдиимидазолом или 1,1'-тиокарбонилдиимидазолом в подходящем растворителе и последующей реакцией продуктов, образованных таким образом, с амином HNR4R5, в котором R4 и R5 имеют значения, определенные в п.1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0414093.5A GB0414093D0 (en) | 2004-06-23 | 2004-06-23 | Novel compounds |
GB0414093.5 | 2004-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007102274A true RU2007102274A (ru) | 2008-07-27 |
RU2382038C2 RU2382038C2 (ru) | 2010-02-20 |
Family
ID=32800053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007102274/04A RU2382038C2 (ru) | 2004-06-23 | 2005-06-21 | Пиперазиндионы как антагонисты рецептора окситоцина |
Country Status (30)
Country | Link |
---|---|
US (9) | US7550462B2 (ru) |
EP (2) | EP1758886B1 (ru) |
JP (2) | JP5405019B2 (ru) |
KR (1) | KR101186447B1 (ru) |
CN (1) | CN1972924B (ru) |
AR (1) | AR049405A1 (ru) |
AU (1) | AU2005256470B2 (ru) |
BR (1) | BRPI0512376A (ru) |
CA (1) | CA2571527C (ru) |
CY (1) | CY1116183T1 (ru) |
DK (1) | DK1758886T3 (ru) |
ES (1) | ES2537801T3 (ru) |
GB (1) | GB0414093D0 (ru) |
HK (2) | HK1106499A1 (ru) |
HR (1) | HRP20150401T1 (ru) |
HU (1) | HUE025869T2 (ru) |
IL (2) | IL179905A0 (ru) |
MA (1) | MA28675B1 (ru) |
MX (1) | MXPA06014545A (ru) |
MY (1) | MY143578A (ru) |
NO (1) | NO338769B1 (ru) |
NZ (1) | NZ551733A (ru) |
PE (1) | PE20060477A1 (ru) |
PL (1) | PL1758886T3 (ru) |
PT (1) | PT1758886E (ru) |
RU (1) | RU2382038C2 (ru) |
SI (1) | SI1758886T1 (ru) |
TW (1) | TWI348466B (ru) |
WO (1) | WO2006000399A1 (ru) |
ZA (1) | ZA200610022B (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0130677D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
EP2392659B1 (en) | 2002-06-17 | 2015-01-14 | Thrasos Innovation, Inc. | Single domain TDF-related compounds and analogs thereof |
GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
WO2006009836A2 (en) | 2004-06-17 | 2006-01-26 | Thrasos Therapeutics, Inc. | Tdf-related compounds and analogs thereof |
GB0414093D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
GB0414100D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
US8299212B2 (en) | 2005-09-20 | 2012-10-30 | Thrasos Therapeutics, Inc. | TDF-related compounds and analogs thereof, analogs and bioactive fragments |
US8716286B2 (en) | 2009-10-30 | 2014-05-06 | Glaxo Group Limited | Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione |
AU2017205254B2 (en) | 2016-01-04 | 2021-05-20 | Xoma (Us) Lcc | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
WO2017203012A1 (en) * | 2016-05-27 | 2017-11-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Epelsiban for use in the treatment of adenomyosis |
MA52548A (fr) | 2016-07-21 | 2021-05-26 | ObsEva SA | Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches |
RU2762019C1 (ru) * | 2018-05-29 | 2021-12-14 | Као Корпорейшн | Способ оценки функциональной способности листа вызывать ощущение комфорта и лист, вызывающий ощущение комфорта |
KR20220075340A (ko) | 2019-09-03 | 2022-06-08 | 옵스에파 에스에이 | 배아 착상을 촉진하고 유산을 예방하기 위한 옥시토신 길항제 투여 요법 |
CN115380122A (zh) | 2020-02-10 | 2022-11-22 | 奥布赛瓦股份公司 | 用于催产素受体拮抗剂疗法的生物标志物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4596819A (en) | 1984-01-23 | 1986-06-24 | Warner-Lambert Company | Modified tripeptides |
DE3830096A1 (de) | 1988-09-03 | 1990-03-15 | Hoechst Ag | Piperazindione mit psychotroper wirkung |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
US5817751A (en) | 1994-06-23 | 1998-10-06 | Affymax Technologies N.V. | Method for synthesis of diketopiperazine and diketomorpholine derivatives |
GB2326639A (en) | 1997-06-18 | 1998-12-30 | Merck & Co Inc | Piperazine Oxytocin Receptor Antagonists |
AU745425B2 (en) | 1998-01-27 | 2002-03-21 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl factor Xa inhibitors |
SK10642000A3 (sk) | 1998-01-29 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Spôsob prípravy n-[(alifatickej alebo aromatickej)karbonyl)]-2- aminoacetamidovej zlúčeniny a cyklizovanej formy tejto zlúčeniny |
AU3087099A (en) | 1998-03-16 | 1999-10-11 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase) |
GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
GB0314733D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
GB0414092D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
GB0414100D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
GB0414093D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
-
2004
- 2004-06-23 GB GBGB0414093.5A patent/GB0414093D0/en not_active Ceased
-
2005
- 2005-06-21 AR ARP050102539A patent/AR049405A1/es not_active Application Discontinuation
- 2005-06-21 US US11/630,179 patent/US7550462B2/en not_active Expired - Fee Related
- 2005-06-21 HU HUE05755563A patent/HUE025869T2/en unknown
- 2005-06-21 RU RU2007102274/04A patent/RU2382038C2/ru not_active IP Right Cessation
- 2005-06-21 JP JP2007517197A patent/JP5405019B2/ja not_active Expired - Fee Related
- 2005-06-21 MY MYPI20052837A patent/MY143578A/en unknown
- 2005-06-21 EP EP05755563.3A patent/EP1758886B1/en active Active
- 2005-06-21 PT PT57555633T patent/PT1758886E/pt unknown
- 2005-06-21 CA CA2571527A patent/CA2571527C/en not_active Expired - Fee Related
- 2005-06-21 EP EP15157368.0A patent/EP2918580A1/en not_active Withdrawn
- 2005-06-21 DK DK05755563T patent/DK1758886T3/da active
- 2005-06-21 AU AU2005256470A patent/AU2005256470B2/en not_active Ceased
- 2005-06-21 PL PL05755563T patent/PL1758886T3/pl unknown
- 2005-06-21 CN CN2005800210140A patent/CN1972924B/zh not_active Expired - Fee Related
- 2005-06-21 WO PCT/EP2005/006760 patent/WO2006000399A1/en active Application Filing
- 2005-06-21 ES ES05755563.3T patent/ES2537801T3/es active Active
- 2005-06-21 SI SI200531963T patent/SI1758886T1/sl unknown
- 2005-06-21 NZ NZ551733A patent/NZ551733A/en not_active IP Right Cessation
- 2005-06-21 KR KR1020067027107A patent/KR101186447B1/ko active IP Right Grant
- 2005-06-21 MX MXPA06014545A patent/MXPA06014545A/es active IP Right Grant
- 2005-06-21 BR BRPI0512376-3A patent/BRPI0512376A/pt not_active Application Discontinuation
- 2005-06-21 TW TW094120517A patent/TWI348466B/zh not_active IP Right Cessation
- 2005-06-22 PE PE2005000714A patent/PE20060477A1/es active IP Right Grant
-
2006
- 2006-11-30 ZA ZA200610022A patent/ZA200610022B/en unknown
- 2006-12-07 IL IL179905A patent/IL179905A0/en not_active IP Right Cessation
- 2006-12-21 MA MA29549A patent/MA28675B1/fr unknown
-
2007
- 2007-01-10 NO NO20070173A patent/NO338769B1/no not_active IP Right Cessation
- 2007-07-23 HK HK07107960.4A patent/HK1106499A1/xx not_active IP Right Cessation
- 2007-07-23 HK HK15109142.1A patent/HK1208669A1/xx unknown
-
2009
- 2009-06-08 US US12/480,182 patent/US20090247541A1/en not_active Abandoned
-
2010
- 2010-08-04 US US12/850,386 patent/US7919492B2/en not_active Expired - Fee Related
-
2011
- 2011-02-25 US US13/035,366 patent/US8202864B2/en not_active Expired - Fee Related
-
2012
- 2012-04-19 US US13/451,196 patent/US20120202811A1/en not_active Abandoned
- 2012-10-05 JP JP2012223526A patent/JP5503709B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-20 US US13/897,853 patent/US8742099B2/en not_active Expired - Fee Related
-
2014
- 2014-04-25 US US14/261,994 patent/US20140235639A1/en not_active Abandoned
-
2015
- 2015-02-16 US US14/623,098 patent/US20150157640A1/en not_active Abandoned
- 2015-03-02 IL IL237513A patent/IL237513A0/en unknown
- 2015-04-08 CY CY20151100339T patent/CY1116183T1/el unknown
- 2015-04-10 HR HRP20150401TT patent/HRP20150401T1/hr unknown
- 2015-10-13 US US14/881,322 patent/US9408851B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007102274A (ru) | Пиперазиндионы как антагонисты рецептора окситоцина | |
US9539243B2 (en) | Triazole compounds that modulate HSP90 activity | |
CN102171214B (zh) | 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 | |
RU2448101C2 (ru) | 5-замещенные изоиндолиновые соединения | |
CA3138182A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
CN108348523A (zh) | 包含pi3k抑制剂和hdac抑制剂的组合物 | |
BR112020017561A2 (pt) | Compostos com atividade indutora de ferroptose e métodos de seu uso | |
CN108290871A (zh) | 具有抗癌活性的mdm2-p53相互作用的异吲哚啉酮抑制剂 | |
AU2019253831B2 (en) | Compositions and methods for treating neurodegenerative diseases | |
CA3131385A1 (en) | Compounds with ferroptosis inducing activity and methods of their use | |
CN109310679A (zh) | 包含组蛋白脱乙酰酶抑制剂的组合 | |
CN112041307A (zh) | 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物 | |
AU2017269871B2 (en) | (8-(phenylsulfonyl)-3,8-diazabicyclo(3.2.1)oct-3-yl) (1H-1,2,3-triazol-4-yl)methanones | |
RU2007102272A (ru) | Замещенные дикетопиперазины в качестве антагонистов | |
WO2020068600A1 (en) | Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof | |
JP7416757B2 (ja) | 置換テトラヒドロシクロペンタ[c]ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
CA3056308A1 (en) | Pharmaceutical compounds | |
BR112020020596A2 (pt) | Método para a preparação de uma 1,2,4-triazolona trissubstituída em 2,4,5 | |
WO2019197269A1 (en) | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer | |
RU2006101859A (ru) | Замещенные дикетопиперазины и их использование в качестве антагонистов окситоцина | |
TW202043203A (zh) | 1,2,4-三-3(2h)-酮化合物 | |
EP3555075A1 (en) | [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones | |
WO2018114672A1 (en) | [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones | |
RU2003126299A (ru) | Замещенные 3-оксо-1,2,3,4-тетрагидрохиноксалины, фармацевтические композиции (варианты), способ их получения и применения | |
NZ740859B2 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180622 |